前往化源商城

69659-80-9 靶点实验数据

HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:24565 靶标:N/A
External ID: ERK5 transcriptional activity-HTS
Protocol: Stable cells plated on a 384-well plate (2500 cells/well) were treated with test compounds at the concentration of 5 muM for 18 hrs. The level of luciferase activity was assayed using a
Luciferase kit (Promega corporation, Madison, WI) and a series of positive and negative control compounds were used as references.
Comment:
Luciferase activity (AU)
104
108
64
28
100
152
176
52
124
44
60
60
32
96
60
144
28
64
84
44
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:ORF 73 [Human herpesvirus 8 type M]
External ID: HMS791
Protocol: Prior to screening, FITC LANA1-23 was stored lyophilized at -80 degC and freshly purified chicken nucleosomes were stored at 4 degC in 20 mM Tris pH 7.5, 600 mM NaCl, 0.2 mM EDTA, 0.5 mM B-Mercaptoethanol.

On the day of screening, FITC LANA1-23 was resuspended at 50 uM in TEN-BT buffer (10 mM Tris-HCl (pH 7.5), 1 mM EDTA (pH 8.0), 2.5 mM NaCl, 5 mM Beta-mercaptoethanol, 0.01% Triton-X-100) and diluted to a final concentration of 50 nM in TEN-BT buffer plus 240 nM of purified nucleosomes (480 nM LANA peptide binding sites). 30 uL per well were dispensed in column 1-22 in Corning #3575 black 384 well plates.

Wells in column 23 contained 30 uL of the same mixture (for pilot screen) or with the addition of 10 uM monensin (for HTS) as a negative control. In column 24, 1250 nM unlabeled WT LANA1-23 peptide (for pilot screen) or 10 uM mitoxantrone (for HTS) was added to the wells as a positive control. Compounds were transferred into wells via stainless steel pin array (100 nL) and the reaction was incubated at room temperature for 10 to 45 minutes (stable for up to 2 hours). Library plates were screened in duplicate, with both assay plates in a given set prepared on the same day.

Following a room temperature incubation of 10 to 45 minutes, the assay is read on a EnVision plate reader using a 480 nM excitation filter, 535 nM S and P emission filters and D505fp/D535 dichoric mirror. mP value for FP measurement = 1000*(S-G*P)/(S+G*P) where S= , P=, G= G-factor. The G Factor = 1.
Comment: LANA 1-23 peptide containing the first 23 amino acids of the LANA protein from Kaposi's sarcoma herpesvirus (KSHV) was synthesized with an N-terminal FITC via a beta alanine linker and HPLC purified (peptide sequence: [FITC]-Beta alanine-MAPPGMRLRSGRSTGAPLTRGSC-[NH2]).

Data analysis: Z-scores were calculated for each replicate well using the mean and standard deviation of plate experimental well FP values. Compounds were considered active if the Z-score for both replicates < -2. Wells with high total fluorescence intensity (high S and P channel values) were excluded from further consideration. Activity scores were calculated based on replicate average FP Z-scores. For wells with average Z-score >= 0, the activity score was set to 0. For wells with replicate average Z-score < 0, replicate Z-score was divided by 4 and multiplied by -100. The replicate average was then used to determine the well activity score. Values > 100 (replicate average Z-score < -4) were set to 100.
FP_AP Channel_AS Channel_AFP_BP Channel_BS Channel_BZ-score_AZ-score_B
91.890.20.1260.03
93.294.90.2610.457
94.892.90.4160.275
89.985.7-0.058-0.379
91.590.10.0970.021
88.789.6-0.174-0.025
92.588.20.194-0.152
91.791.60.1160.157
93.391.20.2710.121
90.586.60-0.297
87.188.8-0.329-0.097
87.685.8-0.28-0.37
89.287.4-0.126-0.224
87.286-0.319-0.351
85.886.1-0.454-0.342
8892-0.2420.193
95.497.70.4740.711
98.697.50.7840.693
9088.4-0.048-0.134
98.693.60.7840.338
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1100
Protocol: DT40-hTDP1 cells without 20 nM Camptothecin (add 20 microL of DMSO in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inactive04-3.0662-2.41261.9741-4.0617-0.6298-3.0662QC'd by "Chem Div"
Inactive04.95490.7346-0.808-4.30840 0 0 0 0-0.431-4.3080.8987-1.5892-1.522-0.431QC'd by "Chem Div"
Inactive04.95490.6448-12.51274.558540 0 0 0 0-9.75096.55851.6006-0.810411.697-9.7509QC'd by "Chem Div"
Inhibitor18.356499.037841Partial curve; high efficacy-4.73622.84730.9985-99.5803-0.5425-2.10 0 0 0 0-92.8278-1.5772-1.93651.8258-13.1847-92.8278QC'd by "Chem Div"
Inhibitor29.092942.181510Single point of activity-4.53624.95490.9879-50.8391-8.6577-30 0 0 0 0-46.8496-7.6387-8.6142-11.6103-6.66-46.8496QC'd by "Chem Div"
Inhibitor18.3564123.871841Partial curve; high efficacy-4.73621.62590.9975-121.45782.414-2.10 0 0 0 0-98.82245.0098-1.1767-0.5372-27.2941-98.8224QC'd by "Chem Div"
Inhibitor14.581109.907342Partial curve; high efficacy-4.83621.82650.9637-106.40863.4987-2.10 0 0 0 0-94.670912.0352-9.70946.0901-28.9742-94.6709QC'd by "Chem Div"
Inactive00.30.9096-34.0578-3.769740 0 0 0 0-28.0098-7.7697-15.2699-21.1534-19.3019-28.0098QC'd by "Chem Div"
Inhibitor29.092990.897810Single point of activity-4.53624.44950.9936-90.33680.561-30 0 0 0 0-79.96355.0637-2.1732-1.69030.5114-79.9635QC'd by "Chem Div"
Inactive00.30.426615.2787-6.721340 0 0 0 010.4803-5.72138.5589-5.30466.71910.4803QC'd by "Chem Div"
Inactive01.96730.6089-9.50825.296840 0 0 0 0-7.95747.2968-1.890310.39461.3036-7.9574QC'd by "Chem Div"
Inhibitor16.360145.504710Single point of activity-4.78624.95490.9618-49.1256-3.6209-30 0 0 0 0-48.9315-7.5358-6.3332.7698-6.0371-48.9315QC'd by "Chem Div"
Inactive0-5.28620.80.9747-26.74278.437240 0 0 0 0-20.71279.43722.29650.248-14.6534-20.7127QC'd by "Chem Div"
Inactive04.95490.9526-10.392812.159440 0 0 0 0-10.30087.659413.806714.3816-9.7278-10.3008QC'd by "Chem Div"
Inactive02.25260.9456-15.0824-3.824740 0 0 0 0-14.7061-2.8247-5.6912-3.1226-9.4063-14.7061QC'd by "Chem Div"
Inhibitor12.995378.844742Partial curve; high efficacy-4.88621.55790.9935-82.5518-3.7072-2.10 0 0 0 0-72.8175-6.4603-0.3489-8.7793-32.8366-72.8175QC'd by "Chem Div"
Inhibitor18.356449.742410Single point of activity-4.73622.84730.9797-46.14163.6008-30 0 0 0 0-42.7679-0.89924.9836.9739-2.5062-42.7679QC'd by "Chem Div"
Inactive04.95490.8308-9.79910.472540 0 0 0 0-5.08718.47258.256110.070916.081-5.0871QC'd by "Chem Div"
Inactive01.88510.9722-5.76856.220540 0 0 0 0-5.0636.2205-1.5445-7.1037-5.5678-5.063QC'd by "Chem Div"
Inactive00.30.842-31.92493.17440 0 0 0 0-26.7418-0.826-13.6909-13.1344-14.0869-26.7418QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2mCherry
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral ininfection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times postinfection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.53 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.39870.9996-13.0836-0.585340 0 0 1-0.8016-2.9877-9.467-12.5697-0.8016QC'd by "Asinex Ltd."
Inhibitor12.589340.511110Single point of activity-4.94.50450.9991-45.3562-4.8451-30 0 0 0-45.0493-5.3378-3.9936-8.2693-45.0493QC'd by "Asinex Ltd."
Inactive040-2.0352000QC'd by "Asinex Ltd."
Inactive04000-0.99410QC'd by "Asinex Ltd."
Inactive04.954910-13.633540 0 0 00-12.1946000QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive04-13.3369-12.1444-5.0835-13.8274-13.3369QC'd by "Asinex Ltd."
Inactive040-4.5112-3.956800QC'd by "Asinex Ltd."
Inactive0400000QC'd by "Asinex Ltd."
Inactive01.80790.9998-19.4131.540 0 0 1-2.29920-11.3763-18.6775-2.2992QC'd by "Asinex Ltd."
Inactive04.95490.77214-15.639840 0 0 00-10.469-15.9421-20.94990QC'd by "Asinex Ltd."
Inactive04.95490.9987-20.1455-0.540 0 0 0-19.28790-0.8113-0.6866-19.2879QC'd by "Asinex Ltd."
Inactive04.95490.9999-7.3207040 0 0 0-6.934000-6.934QC'd by "Asinex Ltd."
Inactive04-10.13410-23.8022-3.1543-10.1341QC'd by "Asinex Ltd."
Inactive01.82650.9999-31.5926140 0 0 1-8.44790-12.323-29.2439-8.4479QC'd by "Asinex Ltd."
Inactive00.70.95422-18.098140 0 0 00-15.9151-9.0083-6.24390QC'd by "Asinex Ltd."
Inactive04.95490.79940.5884-8.240 0 0 0-1.1763-9.1365-5.7126-9.75-1.1763QC'd by "Asinex Ltd."
Inactive00.60.9653-16.23140.75640 0 0 0-14.3595-3.5367-8.6422-10.5182-14.3595QC'd by "Asinex Ltd."
Inactive04-3.3063-1.5829-0.45720-3.3063QC'd by "Asinex Ltd."
Inactive04.95490.7973-6.6878-1.540 0 0 10-2.54350-5.57310QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:TDP1 protein [Homo sapiens]
External ID: TDP1101
Protocol: DT40-hTDP1 cells with 20 nM Camptothecin (add 20 microL of 1 mM CPT stock in 1 L of cell culture medium) were dispensed at 400 cells/5microL/well in tissue culture treated 1536-well white wall/solid bottom assay plates (Greiner Bio-One North America, NC, U.S.A.) using a Multidrop Combi 8 channel dispenser (Thermo Fisher, Waltham, MA, USA). 23 nL compounds and controls were transferred using the pin tool (Kalypsys, San Diego, CA, USA) to the assay plates. The assay plates were then incubated at 37 masculineC for a minimum 48 hr. Three microL of Cell Titer Glo solution was added to the plates and incubated at RT in dark for 30 min. Luminescence was read using ViewLux (Perkin Elmer) with 1 sec exposure slow speed, high gain and 2x binning.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000295000 uMActivity at 0.0000590000 uMActivity at 0.0001503265 uMActivity at 0.0002712146 uMActivity at 0.0005895491 uMActivity at 0.00117 uMActivity at 0.00179 uMActivity at 0.00299 uMActivity at 0.00672 uMActivity at 0.014 uMActivity at 0.026 uMActivity at 0.040 uMActivity at 0.074 uMActivity at 0.167 uMActivity at 0.363 uMActivity at 0.628 uMActivity at 0.975 uMActivity at 1.849 uMActivity at 4.119 uMActivity at 9.037 uMActivity at 15.83 uMActivity at 21.08 uMActivity at 46.23 uMActivity at 92.54 uMActivity at 165.6 uMCompound QC
Inhibitor20.5962118.89141Partial curve; high efficacy-4.68622.30310.9994-116.16692.7241-2.10 0 0 0 0-99.94512.72414.25720.7717-13.7373-99.9451QC'd by "Asinex Ltd."
Inactive00.80.9749-16.17712.005740 0 0 0 0-13.14662.00571.2486-2.8352-5.7162-13.1466QC'd by "Asinex Ltd."
Inactive04.95490.6148-11.8012.205940 0 0 0 0-9.7999-4.79413.64526.73633.1419-9.7999QC'd by "Asinex Ltd."
Inactive0-5.03622.33320.9795-28.8852-5.272340 0 0 0 0-28.1997-7.2723-3.3531-4.7215-17.5124-28.1997QC'd by "Asinex Ltd."
Inhibitor5.173594.688584Complete curve; high efficacy-5.28622.90230.9917-96.1842-1.4957-1.10 0 0 0 0-96.0073-7.53084.5779-6.8491-81.1577-96.0073QC'd by "Asinex Ltd."
Inhibitor18.356494.01210Single point of activity-4.73623.62720.9999-96.5346-2.5226-30 0 0 0 0-93.107-2.9055-1.9361-2.363-9.7613-93.107QC'd by "Asinex Ltd."
Inactive04.95490.8434-31.3086-2.25540 0 0 0 0-27.0497-0.755-10.5210.92280.8125-27.0497QC'd by "Asinex Ltd."
Inactive04.44950.7303-25.728-7.249240 0 0 0 0-25.3982-8.7492-13.51280.9177-19.0413-25.3982QC'd by "Asinex Ltd."
Inhibitor20.5962100.541141Partial curve; high efficacy-4.68622.09370.998-104.3872-3.8461-2.10 0 0 0 0-88.9539-4.1551-2.0443-7.1093-18.8654-88.9539QC'd by "Asinex Ltd."
Inhibitor29.092991.413310Single point of activity-4.53624.95490.9947-88.35973.0536-30 0 0 0 0-79.845-1.16852.65594.53855.7131-79.845QC'd by "Asinex Ltd."
Inactive04.95490.786-1.849912.995440 0 0 0 116.19477.995418.22950.5262-1.875716.1947QC'd by "Asinex Ltd."
Inactive04.95490.9259-4.54544.383940 0 0 0 0-3.72395.38394.7472.6664.8335-3.7239QC'd by "Asinex Ltd."
Inactive0-6.23624.95490.9762-1.408619.454340 0 0 0 01.208619.454317.7088-3.3481-2.37561.2086QC'd by "Asinex Ltd."
Inactive04.95490.4363-4.5616-11.561640 0 0 0 0-4.5336-11.5616-1.6565-10.5162-2.2482-4.5336QC'd by "Asinex Ltd."
Inactive00.70.98896.5184-6.981640 0 0 0 02.8921-7.4816-5.7762-3.9537-1.52422.8921QC'd by "Asinex Ltd."
Inactive04.95490.5926-22.1394-0.155940 0 0 0 0-20.8088-4.1559-8.30412.2914-0.0696-20.8088QC'd by "Asinex Ltd."
Inhibitor29.092964.218610Single point of activity-4.53624.95490.9684-70.1227-5.9041-30 0 0 0 0-64.396-9.2052-0.418-11.9994-2.9068-64.396QC'd by "Asinex Ltd."
Inactive01.210.9644-26.92634.843740 0 0 0 0-17.96476.84374.96630.5719-1.9517-17.9647QC'd by "Asinex Ltd."
Inactive04.95490.9261-29.9871.936440 0 0 0 0-26.99980.4364-0.7582-0.45327.9656-26.9998QC'd by "Asinex Ltd."
Inactive04.0950.45761.780312.60740 0 0 0 06.613211.107-4.99860.1865.25796.6132QC'd by "Asinex Ltd."
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL5519231
Protocol: N/A
Comment: Journal: Eur J Med Chem
Year: 2024
Volume: 265
First Page: 116044
Last Page: 116044
DOI: 10.1016/j.ejmech.2023.116044
Standard TypeStandard UnitsActivity Comment
Inhibition%Active
Inhibition%Active
Inhibition%Active
Inhibition%Active
Inhibition%Active
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23265 靶标:IucA Synthetase from hypervirulent Klebsiella pneumoniae hvKP1
External ID: IucA Pilot Assay Spectrum Library
Protocol: A solution containing 55.6 mM HEPES pH 7.5, 0.11% Tween 20, 16.7 mM MgCl2, 55.6 mM hydroxylamine, 55.6 microM ATP, 55.6 microM citrate, and 0.28 U/mL IPP was dispensed (45 microL) into clear polystyrene microplates (Corning, Inc.) using a BioTek MicroFlo dispenser.

Next, 40 nL of test compounds (10 mM in DMSO, 8 microM final concentration) were transferred from deep-well blocks to the reaction solution using a stainless-steel pin tool operated by a robotic workstation (JANUS, PerkinElmer, Waltham, MA). The IucA-catalyzed reaction was initiated by adding 5 microL of 3 microM IucA in 25 mM HEPES, 75 mM NaCl, and 0.1 mM TCEP at pH 7.5.

The reactions were allowed to proceed for 30 min at room temperature before being quenched by dispensing (microFill, BioTek) 13 microL of MG developing solution, containing 1.0 mg/mL MG oxalate, 1.5% (w/v) ammonium molybdate, 0.15% (v/v) Tween 20, and 4.7 N sulfuric acid. After allowing the assay color to develop/stabilize for 30 min, the absorbance at 620 nm was measured (EnVision 2103 Multilabel Microplate Reader, PerkinElmer).

Average positive controls from 24 wells with no test compound and average negative controls from 8 wells with no enzyme were calculated. Dynamic range was calculated by difference between Avg Pos Control and Avg Neg Control. Percent inhibition was calculated by the ratio of (Avg. Pos. Ctrl - Sample OD) to Dynamic Range.
Comment: Protein Target is
IucA

EMB09144
574 aa
G057_19877
Klebsiella pneumoniae hvKP1

Active compounds were defined by <80% activity at 8 microM screening concentration.
OD%Activity384ID
1.054109.5793076877485A04
1.048108.5123881216295A05
1.085115.0917254460325A06
1.154127.3613004564045A07
1.12121.3154229150615A08
1.115120.4263232766295A09
1.126122.3823424811815A11
1.154127.3613004564045A12
1.138124.5161816134195A13
1.17130.2064192993895A14
1.155127.5391203840915A16
1.128122.7379823365545A17
1.156127.7169403117785A18
1.053109.4014877600625A19
1.052109.2236678323755A20
1.067111.8909667476735A21
1.032105.6672692786445A22
1.062111.0018671092415B03
1.091116.1586450121515B06
1.108119.1815837828235B08
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Replicase polyprotein 1ab
External ID: CHEMBL4495582
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4523582
ChEMBL Target Name: Replicase polyprotein 1ab
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=13.77%
Inhibition=2.35%
Inhibition=21.17%
Inhibition=18.36%
Inhibition=5.381%
Inhibition=18.17%
Inhibition=10.15%
Inhibition=29.56%
Inhibition=18.27%
Inhibition=11.42%
Inhibition=15.4%
Inhibition=7.437%
Inhibition=-3.216%
Inhibition=18%
Inhibition=1.021%
Inhibition=16.4%
Inhibition=2.544%
Inhibition=19.11%
Inhibition=26.15%
Inhibition=5.133%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:67.9K protein [Vaccinia virus]
External ID: Vaccinia-p2Venus
Protocol: A549 cells were plated at a concentration of approximately 6,000 cells per well in clear-bottom black-walled plates. Compounds were added to the assay plate followed by addition of virus (LREV) that expresses the Venus fluorescent protein early in viral infection. During the late viral infection, mCherry was also added to the plate at an MOI of 10 (~ 60,000 plaque forming units (PFU) of virus). Following virus addition, plates were incubated in a tissue-culture incubator for 12-18 hours. At increasing times post-infection, fluorescence from both Venus and mCherrry was determined using a plate-reader and standard conditions for observing Venus fluorescence (EX515/EM530) and mCherry fluorescence (EX587/EM610). In each plate, positive controls (virus infection in the presence of 1% DMSO only) and an inhibitory drug control (AraC at 500 nM) was included and used to normalize the data.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00111 uMActivity at 0.00284 uMActivity at 0.00446 uMActivity at 0.00891 uMActivity at 0.015 uMActivity at 0.029 uMActivity at 0.036 uMActivity at 0.073 uMActivity at 0.113 uMActivity at 0.149 uMActivity at 0.293 uMActivity at 0.487 uMActivity at 0.726 uMActivity at 1.458 uMActivity at 2.011 uMActivity at 3.331 uMActivity at 5.199 uMActivity at 7.343 uMActivity at 13.78 uMActivity at 20.90 uMActivity at 36.52 uMActivity at 60.71 uMActivity at 87.88 uMActivity at 127.3 uMActivity at 194.0 uMCompound QC
Inactive01.46410.71-12.454-240 0 0 0-11.2117-5.20930.6206-7.2594-11.2117QC'd by "Chem Div"
Inactive04-11.3429-16.0267-12.2608-14.6132-11.3429QC'd by "Chem Div"
Inactive01.62590.9272-14.3148-0.87740 0 0 0-15.2623-7.8142-13.6096-13.0621-15.2623QC'd by "Chem Div"
Inactive04-12.3142-9.814-12.586-8.4662-12.3142QC'd by "Chem Div"
Inactive04-8.2677-9.1999-12.2836-11.2753-8.2677QC'd by "Chem Div"
Inactive04.50450.9238-23.3577-9.005740 0 0 0-23.2147-6.6714-11.5717-9.7492-23.2147QC'd by "Chem Div"
Inhibitor11.220218.895721Partial curve; partial efficacy-4.953.51170.9065-31.7758-12.8801-2.20 0 0 0-31.4798-16.0985-9.0667-16.5103-31.4798QC'd by "Chem Div"
Inactive04.95490.8003-13.5254-8.878340 0 0 0-13.3545-10.4528-7.3986-12.9731-13.3545QC'd by "Chem Div"
Inactive02.33320.9015-5.5393840 0 0 0-5.44945.481810.30710-5.4494QC'd by "Chem Div"
Inactive01.96730.9741-21.6735-12.493740 0 0 0-21.3946-13.4008-12.078-16.6303-21.3946QC'd by "Chem Div"
Inactive04-5.6419-17.3934-2.7552-14.5706-5.6419QC'd by "Chem Div"
Inactive04.95490.8944-16.0102-8.684840 0 0 0-15.0085-7.2373-9.9603-8.6791-15.0085QC'd by "Chem Div"
Inactive01.55790.9997-19.5854-2.051340 0 0 1-5.8527-2.9594-9.4187-17.9878-5.8527QC'd by "Chem Div"
Inactive00.90.997418-20.238340 0 0 012.7737-17.6986-10.21151.105512.7737QC'd by "Chem Div"
Inactive01.88510.9998-14.291-6.778340 0 0 1-6.726-6.8986-8.4505-13.1591-6.726QC'd by "Chem Div"
Inactive00.90.9901-24.8053-6.556940 0 0 0-19.0044-6.7141-9.2211-12.2131-19.0044QC'd by "Chem Div"
Inhibitor1025.752521Partial curve; partial efficacy-54.95490.9958-34.5683-8.8157-2.20 0 0 0-34.709-9.7184-7.7631-13.3604-34.709QC'd by "Chem Div"
Inactive00.50.7446-13.2445-2.110940 0 0 0-9.3704-2.5924-6.2168-4.8236-9.3704QC'd by "Chem Div"
Inactive04.95490.8017-7.4285-18.016840 0 0 0-7.4434-13.764-5.7738-9.5578-7.4434QC'd by "Chem Div"
Activator31.6228490Partial curve; high efficacy-4.50.80.9998651142.10 0 0 1118.3965112.9568110.0983102.4909118.3965QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303810
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueActivity Comment
Hit score=0.07667
Hit score=0.08432
Hit score=0.03233
Hit score=0.1032N=2 (0.182401631,0.023899107)
Hit score=0.0587
Hit score=0.04532
Hit score=0.1213
Hit score=0.1255
Hit score=0.1871
Hit score=0.2217
Hit score=0.1243
Hit score=0.1603
Hit score=0.2724
Hit score=0.3773
Hit score=0.1041
Hit score=0.2216
Hit score=0.6828
Hit score=0.3285
Hit score=0.1291
Hit score=0.1698
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:N/A
External ID: CHEMBL5519218
Protocol: N/A
Comment: Compounds with activity <= 10uM or explicitly reported as active by ChEMBL are flagged as active in this PubChem assay presentation.

Journal: Eur J Med Chem
Year: 2024
Volume: 265
First Page: 116044
Last Page: 116044
DOI: 10.1016/j.ejmech.2023.116044
PubChem Standard ValueStandard TypeStandard RelationStandard ValueStandard Units
7.52IC50=7520nM
6.54IC50=6540nM
4.58IC50=4580nM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:gene 4 small orf - Marburg virus
External ID: VSVM-OFFLINE
Protocol: Two uL of HEK293 cell suspension are dispensed at 1000 cells/well into solid white 1536-well plates (Grenier) using a Multidrop Combi (Thermo Scientific). After addition of 23 nL compound by a pin tool (Kalypsys), the plate is incubated 1 h at 37 degrees C and then 3 uL of virus 1:100 dilution VSV-MARV is added. After 28 hr, 4 uL of assay reagent is added and the plates are read using a ViewLux (Perkin Elmer). Assays are performed in sub-saturating amounts of virus (MOI <0.5), therefore luciferase signals reflect the amount (titer) of virus able to infect the cells in presence of the compound.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.589 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inactive04.95490.4153-14.5146140 0 0 0 14.685-8.53350.780711.3474-12.51224.685QC'd by "Microsource"
Activator12.589329.27050Single point of activity-4.94.95490.9612311.729530 0 0 0 030.9001-1.47541.01665.62436.608330.9001QC'd by "Microsource"
Activator8.912565.96990Partial curve; partial efficacy-5.050.60.947860.7629-5.2072.20 0 0 0 046.0767-2.32250.745918.756422.519446.0767QC'd by "Microsource"
Inactive04.95490.3508-5.42411240 0 0 0 02.8246.9985-6.3081-17.4367-1.02662.824QC'd by "Microsource"
Inactive04.0950.8518-20.6942-4.843241 0 0 0 0-16.9639-25.916-5.286-19.6983-24.7451-16.9639QC'd by "Microsource"
Inactive04.95490.8518-16.29641.540 0 0 0 14.12061.8961-0.6171-21.497-11.42484.1206QC'd by "Microsource"
Activator2.238783.66590Partial curve; partial efficacy; poor fit-5.650.50.880654.0974-29.56852.40 0 0 0 044.3794-19.3312-4.132918.849613.579244.3794QC'd by "Microsource"
Inhibitor12.589381.174742Partial curve; high efficacy-4.94.0950.9407-88.2352-7.0605-2.10 0 0 0 0-88.059-2.11412.5457-21.0606-24.383-88.059QC'd by "Microsource"
Inactive00.80.97540.51840 0 0 0 00.168615.59399.55235.23893.39690.1686QC'd by "Microsource"
Inactive04.95490.51614-11.192240 0 0 0 08.92332.0681-9.5798-21.4101-15.0678.9233QC'd by "Microsource"
Inhibitor10111.457810Partial curve; high efficacy; poor fit-54.0950.8557-88.020423.4373-2.30 0 0 0 0-86.9630.137116.114955.0816-24.8092-86.963QC'd by "Microsource"
Inhibitor12.5893111.860910Single point of activity-4.91.39870.9539-66.693445.1675-30 0 0 0 0-51.905634.889558.259132.6243.3045-51.9056QC'd by "Microsource"
Inactive049.450123.472150.1914-0.877627.49679.4501QC'd by "Microsource"
Inactive03.62720.9908-9.607722.540 0 0 0 0-9.256421.990720.604224.22328.6092-9.2564QC'd by "Microsource"
Activator0Single point of activity4.95490.354725.2512530 0 0 0 115.41425.71766.534243.23167.091915.4142QC'd by "Microsource"
Inactive04.95490.6074718.540 0 0 0 011.651512.589721.593821.22094.311811.6515QC'd by "Microsource"
Activator2.238752.78950Partial curve; partial efficacy-5.652.25260.961344.2358-8.55372.20 0 0 0 1-9.4264-2.4981-13.18211.959142.1127-9.4264QC'd by "Microsource"
Inactive04.95490.942281.190940 0 0 0 11.53164.67291.2372-2.34124.44781.5316QC'd by "Microsource"
Inhibitor35.481355.762210Single point of activity-4.454.95490.7876-42.791512.9707-30 0 0 0 0-30.683914.51513.87134.773829.0235-30.6839QC'd by "Microsource"
Inhibitor35.481349.231710Single point of activity-4.454.44950.7066-51.9324-2.7008-30 0 0 0 0-40.193-17.989111.8148-5.59920.7455-40.193QC'd by "Microsource"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: VSVL-OFFLINE
Protocol: For screening, 1000 cells in 2 ul/well were dispensed into white solid 1536-well plates (Greiner) using a solenoid-based dispenser. Following transfer of 23nl compound or DMSO vehicle by a pin tool, 3 ul/well of VSV-LV was added. The plates were centrifuged 1 min at 1000 RPM and then incubated 16 hr at 37 C and 5% CO2. After addition of 4 ul/well SteadyLite (PerkinElmer) detection reagent, the plates were incubated 10 min at ambient temperature and luminescence was measured on a ViewLux (Perkin Elmer) plate reader.

Keywords: NIH Roadmap, MLPCN, MLI, MLSMR, qHTS, NCGC, Lassa virus, luciferase, cell assay, infection
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0000000311 uMActivity at 0.0000000880 uMActivity at 0.0000001756 uMActivity at 0.0000004972 uMActivity at 0.0000014063 uMActivity at 0.0000028127 uMActivity at 0.0000079555 uMActivity at 0.0000225014 uMActivity at 0.0000450029 uMActivity at 0.0001299230 uMActivity at 0.0003002708 uMActivity at 0.0008965874 uMActivity at 0.00268 uMActivity at 0.00700 uMActivity at 0.016 uMActivity at 0.032 uMActivity at 0.076 uMActivity at 0.219 uMActivity at 0.631 uMActivity at 1.728 uMActivity at 3.886 uMActivity at 8.587 uMActivity at 17.80 uMActivity at 49.20 uMActivity at 107.3 uMActivity at 231.0 uMCompound QC
Inhibitor25.118946.394520Partial curve; partial efficacy-4.62.25260.9287-51.2557-4.8612-2.20 0 0 0 0-41.1028-5.7868-8.9838-1.9677-26.4188-41.1028QC'd by "BIOMOL"
Inactive03.51170.943510-4.56740 0 0 0 1-5.6299-3.6518-3.5753-4.22256.795-5.6299QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.937611-2.769540 0 0 0 1-2.8045-1.4193-3.1412-1.90487.584-2.8045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.76251-16.740 0 0 0-0.288-12.255.019-2.495-0.288QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.83354.5-7.094640 0 0 03.0138-4.24556.66523.43423.0138QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9930.5-16.289540 0 0 0 1-17.2531-11.90790.45770.74590.1472-17.2531QC'd by "Prestwick Chemical; Inc."
Inactive03.06540.989-13.9862-8.196440 0 0 0-13.7385-8.6044-8.0804-9.4725-13.7385QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.8435-11.2843440 0 0 0 0-11.90363.48785.23930.52915.9839-11.9036QC'd by "Prestwick Chemical; Inc."
Inactive00.80.72410.6-14.699940 0 0 0 1-12.1307-11.4165-6.1179-8.0206-2.8333-12.1307QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.86521-19.704140 0 0 0 0-4.2947-18.0867-15.93714.83952.1157-4.2947QC'd by "Prestwick Chemical; Inc."
Inhibitor14.125442.146510Single point of activity-4.854.95490.8997-40.14652-30 0 0 0 0-41.8192-2.3935.1804-2.52484.6867-41.8192QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.6566-10.2454040 0 0 0 0-10.2045-4.5492-0.09894.6103-5.6017-10.2045QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.52793-11.352240 0 0 01.078-15.7102-2.9932-14.95471.078QC'd by "Prestwick Chemical; Inc."
Inactive01.69240.91230.5-10.14740 0 0 00.4297-9.2892-3.9336-3.15660.4297QC'd by "Prestwick Chemical; Inc."
Inactive02.40640.78868-4.302940 0 0 0 05.7256-1.9822-4.4191-3.81758.01425.7256QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9975.5-12.07640 0 0 1-6.5693-12.5633-7.49474.9219-6.5693QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.9232-18.4489-2.283740 0 0 0-16.2075-1.3456-4.9534-0.2364-16.2075QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.94812-17.564340 0 0 0 1-13.5121-12.97033.62471.45070.7522-13.5121QC'd by "Prestwick Chemical; Inc."
Inactive04.95490.5725-10.21937.540 0 0 0 0-12.75555.8917.5423-18.51610.6587-12.7555QC'd by "Prestwick Chemical; Inc."
Inhibitor31.6228100.706940Partial curve; high efficacy-4.53.57220.9933-104.0783-3.3715-2.10 0 0 0 0-83.39610.3188-7.6251-4.9588-20.5702-83.3961QC'd by "BIOMOL"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-activator-f1f2f3f4
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0008905393 uMActivity at 0.00133 uMActivity at 0.00260 uMActivity at 0.00420 uMActivity at 0.00779 uMActivity at 0.011 uMActivity at 0.023 uMActivity at 0.033 uMActivity at 0.070 uMActivity at 0.092 uMActivity at 0.148 uMActivity at 0.213 uMActivity at 0.447 uMActivity at 0.637 uMActivity at 1.271 uMActivity at 1.910 uMActivity at 3.487 uMActivity at 5.719 uMActivity at 10.47 uMActivity at 17.11 uMActivity at 29.50 uMActivity at 51.33 uMActivity at 83.48 uMActivity at 153.7 uMActivity at 271.3 uMActivity at 313.8 uMCompound QC
Inactive0-4.210.854215-0.814140 0 0 0 0 0 0 012.47610.61490.1958-4.84511.0169-0.16650.92927.32412.4761QC'd by Chem Div
Inactive00045.5368-0.1521-0.48530.81233.044.35085.5368QC'd by Chem Div
Inactive00048.60424.86186.00054.85722.40882.55011.87353.33368.6042QC'd by Chem Div
Inactive0004-2.88031.5268-0.8493-0.86114.1068-1.778-0.0897-1.4954-2.8803QC'd by Chem Div
Inactive00046.69795.85144.53873.26556.71933.13773.82684.83146.6979QC'd by Chem Div
Inactive000411.26423.91961.89474.75392.74994.395111.2642QC'd by Chem Div
Inactive00044.34292.9262-0.18853.24881.5027-2.50024.3429QC'd by Chem Div
Inactive0004-0.68293.35561.39732.46983.71382.6913-0.6829QC'd by DPISMR
Inactive00044.10942.9782.9594-0.21373.96293.24447.01052.24494.1094QC'd by ChemBridge
Inactive0-3.910.7748300.685240 0 0 0 0 0 0 023.31094.92231.4858-0.26241.7621-0.08891.75686.642923.3109QC'd by ChemBridge
Inactive00047.22591.12572.50452.1182.1360.31087.2259QC'd by DPISMR
Inactive00042.76816.76342.22783.34190.98461.31152.76713.38112.7681QC'd by ChemBridge
Inactive0-4.110.842918-0.163240 0 0 0 0 0 0 013.83342.76191.5007-1.44281.3099-2.6361.86187.598213.8334QC'd by ChemBridge
Inactive00045.8128-3.60751.45912.0274-0.4652-4.9165.8128QC'd by ChemBridge
Inactive0-3.9510.7398-12.738-0.540 0 0 0 0 0-8.9483-1.7034-0.1105-2.14621.7984-5.297-8.9483QC'd by ChemBridge
Inactive0004-2.5811-8.353-2.4919-8.4727-4.4155-5.0949-1.5077-0.4001-2.5811QC'd by ChemBridge
Inactive0-4.4510.7869-2940 0 0 0 0 0 0 00.175111.52147.2935.777410.98237.5586.131.27520.1751QC'd by ChemBridge
Inactive0-3.9510.844324-0.688340 0 0 0 0 0 0 017.1313-1.35951.4567-3.49020.35182.67021.93716.15817.1313QC'd by ChemBridge
Inactive0-6.6510.43633-6.18840 0 0 0 0 07.2613-3.491.14993.89341.143-1.03677.2613QC'd by ChemBridge
Inactive00.60.956-7.38787.540 0 0 0 0 0 0 0 0 0 0-7.40656.37485.78158.52675.20314.23673.0265-1.7308-2.2978-3.391-4.7307-7.4065QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-inhibitor-f1f2f3f4
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0006653454 uMActivity at 0.0009950977 uMActivity at 0.00194 uMActivity at 0.00314 uMActivity at 0.00582 uMActivity at 0.00823 uMActivity at 0.017 uMActivity at 0.024 uMActivity at 0.052 uMActivity at 0.069 uMActivity at 0.111 uMActivity at 0.159 uMActivity at 0.334 uMActivity at 0.476 uMActivity at 0.949 uMActivity at 1.427 uMActivity at 2.605 uMActivity at 4.273 uMActivity at 7.820 uMActivity at 12.78 uMActivity at 22.04 uMActivity at 38.35 uMActivity at 62.38 uMActivity at 114.8 uMActivity at 202.7 uMActivity at 234.5 uMCompound QC
Inhibitor3.141491.565384Complete curve; high efficacy-5.50291.10.996-83.56538-1.10 0 0 0 0 0 0 0 0 0 0-83.39855.86425.17526.892210.90315.38042.223-20.9811-45.6671-65.9774-77.4953-83.3985QC'd by SigmaAldrich
Inhibitor7.568673.19383Complete curve; high efficacy-5.1211.78850.9952-82.8887-9.6957-1.10 0 0 0 0 0 0 0-80.375-9.2369-7.6804-7.6509-14.8323-17.372-58.9614-82.7971-80.375QC'd by Chem Div
Inhibitor9.5283113.41783Complete curve; high efficacy-5.0212.04790.9957-126.8199-13.4029-1.10 0 0 0 0 0 0 0-128.8821-12.2785-9.679-19.3504-12.0769-19.5794-82.8273-119.9921-128.8821QC'd by Asinex Ltd.
Inhibitor8.912597.094183Complete curve; high efficacy-5.051.41630.9972-95.91371.1804-1.10 0 0 0 0 0-95.1525-2.22623.0431-10.9978-55.3438-87.9728-95.1525QC'd by Key Organics Ltd.
Inhibitor7.568680.84283Complete curve; high efficacy-5.1211.86170.99-94.8681-14.0261-1.10 0 0 0 0 0 0 0-88.9598-9.2218-14.3086-16.5014-16.2031-22.3172-68.1032-98.8209-88.9598QC'd by Sigma Chemical Company
Inhibitor9.5283107.83683Complete curve; high efficacy-5.0210.80.9912-121.2518-13.4158-1.10 0 0 0 0 0 0 0-109.8296-16.8462-9.939-19.9812-16.655-43.876-69.7913-99.6793-109.8296QC'd by Asinex Ltd.
Inhibitor9.5283102.410283Complete curve; high efficacy-5.0212.25260.9928-112.0345-9.6243-1.10 0 0 0 0 0 0 0-116.7026-13.4215-5.2335-14.5215-9.9722-10.6725-70.1375-106.0787-116.7026QC'd by InterBioScreen
Inhibitor6.7456100.747783Complete curve; high efficacy-5.1712.04790.9883-102.4434-1.6957-1.10 0 0 0 0 0 0 0-110.1541-0.6199-3.1798-6.28492.8918-11.5064-77.2529-92.783-110.1541QC'd by InterBioScreen
Inhibitor8.4921112.57283Complete curve; high efficacy-5.0712.04790.9978-114.9669-2.3949-1.10 0 0 0 0 0 0 0-112.6964-0.4977-0.1079-6.8481-0.5406-11.4336-76.2713-113.3796-112.6964QC'd by Chem Div
Inhibitor9.5283100.648483Complete curve; high efficacy-5.0211.78850.9962-100.64840-1.10 0 0 0 0 0 0 0-102.91253.22740.2085-3.8063-2.2579-5.9804-58.4009-93.2587-102.9125QC'd by InterBioScreen
Inhibitor7.032775.807582Complete curve; high efficacy-5.15291.210.9887-67.80758-1.10 0 0 0 0 0 0 0 0 0 0-62.73296.41369.1587.55816.57045.82533.26394.0875-18.7337-46.8788-54.1698-62.7329QC'd by Timtec
Inhibitor9.528377.680982Complete curve; high efficacy-5.0211.22210.9944-83.7222-6.0413-1.10 0 0 0 0 0 0 0-81.7738-4.3587-3.5127-10.8793-7.6754-16.5948-51.1312-73.833-81.7738QC'd by InterBioScreen
Inhibitor10.69175.705882Complete curve; high efficacy-4.9711.96730.9723-81.5585-5.8527-1.10 0 0 0 0 0 0 0-71.231-3.7858-1.8418-9.4119-9.4119-9.0819-46.725-88.2668-71.231QC'd by Chem Div
Inhibitor6.01299.425582Complete curve; high efficacy-5.2210.40.9552-66.407633.018-1.10 0 0 0 0 0 0 0-48.549732.930223.856811.2161.8455-3.1495-12.7102-42.9961-48.5497QC'd by InterBioScreen
Inhibitor12.589384.403582Complete curve; high efficacy-4.92.72020.9858-86.2417-1.8382-1.10 0 0 0 0 0-85.6842.3129-10.93951.6385-38.1285-86.0696-85.684QC'd by Nathanael S Gray - Dana Farber Cancer Institute - MLI PSL
Inhibitor12.589381.614682Complete curve; high efficacy-4.92.33320.999-91.3016-9.687-1.10 0 0 0 0 0-91.1194-8.8096-11.8548-10.1481-45.0265-88.9937-91.1194QC'd by InterBioScreen
Inhibitor13.459186.958882Complete curve; high efficacy-4.8711.46410.9849-93.9971-7.0383-1.10 0 0 0 0 0 0 0-84.5472-4.3953-7.2317-9.2129-14.3512-7.0393-45.0179-87.0343-84.5472QC'd by InterBioScreen
Inhibitor8.912591.139782Complete curve; high efficacy-5.054.0950.9946-89.05642.0833-1.10 0 0 0 0 0-93.35055.8165-1.44992.1549-65.2799-85.2894-93.3505QC'd by Enamine
Inhibitor15.101490.259882Complete curve; high efficacy-4.8212.40640.9711-110.2608-20.001-1.10 0 0 0 0 0 0 0-98.3869-17.9349-21.0527-21.4562-23.8802-18.187-46.7884-119.3299-98.3869QC'd by NCI Chemotherapeutic Agents Repository
Inhibitor15.744190.090881Complete curve; high efficacy-4.80291.66040.9839-89.14830.9425-1.10 0 0 0 0 0 0 0 0 0 0-83.94382.9677.20542.7371-0.61222.788-2.9535-4.3083-13.5377-29.9354-76.8118-83.9438QC'd by SigmaAldrich
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-activator-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Activator112.20182659.1944100Partial curve; high efficacy-3.954.50450.99882689.2430.04562.10 0 0 0 0 02175.7605-2.186418.44120.797383.3849426.79582175.7605QC'd by Microsource
Activator0.1778128.312895Complete curve; high efficacy-6.754.95490.9927134.48516.17231.10 0 0 0 0 114.5095.603324.7938142.7655131.831127.775314.509QC'd by SigmaAldrich
Activator0.4467126.107791Complete curve; high efficacy-6.351.86170.9998123.6363-2.47141.10 0 0 0 0 10.2688-2.58447.816180.257120.2764123.38950.2688QC'd by SigmaAldrich
Activator1.122117.125490Complete curve; high efficacy-5.952.24810.9788132.426515.30111.10 0 0 0 0143.318715.809439.5652122.9227119.7824143.3187QC'd by Tocris
Activator112.20181122.177671Partial curve; high efficacy-3.954.50450.99831140.568818.39122.10 0 0 0 0922.79033.23057.588941.6506204.8302922.7903QC'd by Timtec
Activator100709.567358Partial curve; high efficacy-43.990.9988700.7079-8.85942.10 0 0 0 0 0592.8155-15.9019-8.65324.5286-20.153176.4838592.8155QC'd by CarsonNewman-SPECS
Activator79.4328826.407657Partial curve; high efficacy-4.14.0950.9972826.76670.35912.10 0 0 0 0 0665.6736-2.5729-3.4508-16.761725.5851154.5978665.6736QC'd by Prestwick Chemical; Inc.
Activator100589.932555Partial curve; high efficacy-43.24750.984613.297923.36542.10 0 0 0 0 0498.6162-5.7471.05937.654362.5313194.9599498.6162QC'd by CarsonNewman-SPECS
Activator112.2018558.656655Partial curve; high efficacy-3.954.50450.9992557.2619-1.39472.10 0 0 0 0448.681-6.8565-3.87677.063281.1858448.681QC'd by Vitas
Activator100612.475355Partial curve; high efficacy-44.50450.9972611.2868-1.18852.10 0 0 0 0 0533.4091-10.048-5.6002-8.206821.4265142.7223533.4091QC'd by Pharmacopeia
Activator100511.551853Partial curve; high efficacy-44.44950.9965517.54675.9952.10 0 0 0 0 0453.9884-10.486710.44483.974421.1983121.4017453.9884QC'd by CarsonNewman-SPECS
Activator112.2018440.198152Partial curve; high efficacy-3.954.0950.9989439.2753-0.92282.10 0 0 0 0348.6312-5.1918-3.30186.970574.6909348.6312QC'd by Sequoia
Activator100497.63552Partial curve; high efficacy-43.67720.9977486.8252-10.80982.10 0 0 0 0 0401.671-14.9427-21.3461-13.18642.6858130.5049401.671QC'd by Pharmacopeia
Activator100438.508551Partial curve; high efficacy-44.95490.9987437.7956-0.71282.10 0 0 0 0 0392.29-7.25310.2913-4.1769.366693.145392.29QC'd by Pharmacopeia
Activator56.2341819.971850Partial curve; high efficacy-4.253.24750.9993802.9227-17.0492.10 0 0 0 0787.1792-7.4836-10.9833-14.2075580.1833787.1792QC'd by NCI
Activator112.2018363.64150Partial curve; high efficacy-3.954.95490.9972355.9752-7.66582.10 0 0 0 0 0293.7089-16.73630.4741-6.1211-4.368934.2599293.7089QC'd by Pharmacopeia
Activator112.2018363.029750Partial curve; high efficacy-3.954.50450.9992370.42997.40022.10 0 0 0 0 0299.70063.69434.700413.02825.857563.7543299.7006QC'd by Pharmacopeia
Activator100295.813448Partial curve; high efficacy-43.62720.9992302.03896.22552.10 0 0 0 0 0251.69912.67988.48118.67789.650486.3825251.6991QC'd by CarsonNewman-SPECS
Activator100233.346946Partial curve; high efficacy-44.50450.9961221.7227-11.62422.10 0 0 0 0 0192.4676-6.6471-16.5394-18.4762-5.603142.3638192.4676QC'd by CarsonNewman-SPECS
Activator112.2018234.606146Partial curve; high efficacy-3.954.95490.984235.23560.62952.10 0 0 0 0 0197.01480.9163-4.51361.948217.44218.7867197.0148QC'd by Pharmacopeia
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac1-inhibitor-v
Protocol: Briefly, three uL of reagents (100 nM EPAC1, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.013 uMActivity at 0.025 uMActivity at 0.042 uMActivity at 0.068 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.78241.505912.540 0 0 0 0 02.50148.657916.73337.679-0.41183.23982.5014QC'd by Pharmacopeia
Inactive04.95490.5059222.540 0 0 0 0 06.253623.167131.574120.397112.323123.69316.2536QC'd by Pharmacopeia
Inactive03.06540.487561440 0 0 0 0 07.117813.853713.063510.239619.91049.84967.1178QC'd by Pharmacopeia
Inactive04.95490.8513-6.122214.540 0 0 0 0 0-2.601918.618115.697111.958910.649712.3116-2.6019QC'd by Pharmacopeia
Inactive04.95490.4441-8.935340 0 0 0 0 04.128-6.61282.85915.135-4.2457-1.68664.128QC'd by Pharmacopeia
Inactive00.90.60781.5740 0 0 0 0 03.28024.93557.52122.24671.45360.76263.2802QC'd by Pharmacopeia
Inactive0415.807823.846715.21025.400717.117711.703815.8078QC'd by Pharmacopeia
Inactive04-4.32494.35640.9262-8.26096.61363.2318-4.3249QC'd by Pharmacopeia
Inactive04.95490.3866.51640 0 0 0 0 118.561314.469622.616710.242516.25858.074118.5613QC'd by Pharmacopeia
Inactive04.95490.793515-5.385140 0 0 0 0 016.1015-1.154320.964112.456114.239511.422716.1015QC'd by Pharmacopeia
Inactive04.50450.947310.52240 0 0 0 0 08.684621.396522.306312.781710.406512.7248.6846QC'd by Pharmacopeia
Inactive00.90.72282.68042640 0 0 0 0 0-2.766319.58196.42455.7298.03594.8741-2.7663QC'd by Pharmacopeia
Inactive04.44950.86116.58.540 0 0 0 0 19.3158.510610.85386.227115.368416.53989.315QC'd by Pharmacopeia
Inactive04.95490.574110.50.708340 0 0 0 0 012.21914.1249-2.326514.46343.839910.786612.2191QC'd by Pharmacopeia
Inactive049.708413.42218.37480.333810.101818.04579.7084QC'd by Pharmacopeia
Inactive04.95490.4502-7.41418.540 0 0 0 0 0-4.51189.055914.9898-2.014610.28748.4395-4.5118QC'd by Pharmacopeia
Inactive04.95490.6758280.244340 0 0 0 0 023.04957.0826-6.46314.13492.386-6.030223.0495QC'd by Pharmacopeia
Inactive04.44950.7608-2.59256.540 0 0 0 0 18.96953.44595.67689.8855-0.0456-2.16048.9695QC'd by Pharmacopeia
Inactive02.63840.66513.52040 0 0 0 0 013.574216.035922.509821.272319.386214.340813.5742QC'd by Pharmacopeia
Inactive04-3.2632-16.2622-13.7616-11.6684-9.5243-17.6211-3.2632QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-inhibitor-f1f2f3f4
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control ATA and DMSO.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0006615435 uMActivity at 0.0009894114 uMActivity at 0.00193 uMActivity at 0.00314 uMActivity at 0.00579 uMActivity at 0.00818 uMActivity at 0.017 uMActivity at 0.024 uMActivity at 0.052 uMActivity at 0.068 uMActivity at 0.110 uMActivity at 0.158 uMActivity at 0.332 uMActivity at 0.473 uMActivity at 0.944 uMActivity at 1.419 uMActivity at 2.593 uMActivity at 4.249 uMActivity at 7.775 uMActivity at 12.71 uMActivity at 21.91 uMActivity at 38.14 uMActivity at 62.54 uMActivity at 114.2 uMActivity at 201.6 uMActivity at 233.1 uMCompound QC
Inhibitor6.74561494.3646100Complete curve; high efficacy-5.1712.63840.965-1503.2555-8.8908-1.10 0 0 0 0 0 0 0-1260.1318-11.1547-6.7992-1.606913.7817-128.8233-1191.5094-1764.3843-1260.1318QC'd by Enamine
Inhibitor0.09531682.33392Complete curve; high efficacy-7.0211.47870.9805-97.06811585.265-1.11 0 0 0 0 0 0 0-38.69643173.90851467.8379734.024261.6921-105.8029-252.970921.2579-38.6964QC'd by Richard A Houghten - Torrey Pines Institute for Molecular Studies - MLI PSL
Inhibitor0.9528462.085591Complete curve; high efficacy-6.0214.95490.8781-147.1919314.8936-1.11 0 1 0 0 0 0 0-170.5569526.5921229.1516847.3074389.4244-222.0195-22.4759-166.4298-170.5569QC'd by Chem Div
Inhibitor0.067524.59186Complete curve; high efficacy-7.1713.19250.4734-42.2643-66.8553-1.10 0 0 0 0 0 0 1-61.4189-67.8557-65.4209-48.882-33.4136-32.3036-35.0315-67.9216-61.4189QC'd by Scott E Schaus - Boston Univ. - MLI CMLD
Inhibitor0.01921.607386Complete curve; high efficacy-7.7213.06540.8497-38.71-60.3172-1.10 0 0 0 0 0-33.8968-60.016-50.4881-38.7102-36.9245-45.4763-33.8968QC'd by Specs
Inhibitor5.548138.182186Complete curve; high efficacy-5.25591.37230.995-149.829-11.6469-1.10 0 0 0 0 0 0 0 0 0 0-146.0322-15.3641-14.426-10.6845-2.5307-13.6678-14.3878-34.5896-65.4595-119.9073-140.2727-146.0322QC'd by Tocris
Inhibitor1.19956.031886Complete curve; high efficacy-5.9214.95490.4811-77.4305-71.3987-1.10 0 0 0 0 0 0 1-69.1964-75.7075-69.7865-73.9043-66.5822-78.692-74.9799-77.8985-69.1964QC'd by NIH Chemical Genomics Center (NCGC)
Inhibitor3.013174.519685Complete curve; high efficacy-5.5211.24750.976-90.5995-16.08-1.10 0 0 0 0 0 0 0-88.471-25.2771-12.4556-14.1585-17.913-51.4226-73.9001-93.7883-88.471QC'd by Key Organics Ltd.
Inhibitor1.694472.743985Complete curve; high efficacy-5.7711.62660.9736-86.1149-13.3709-1.10 0 0 0 0 0 0 0-90.2672-16.7468-16.0693-11.6766-14.4415-64.3096-72.7308-87.9452-90.2672QC'd by Asinex Ltd.
Inhibitor0.151140.645685Complete curve; high efficacy-6.8210.90.9849-44.2164-184.862-1.10 0 0 0 0 0-53.3465-180.1774-166.0242-127.2248-89.878-43.6723-53.3465QC'd by Sytravon
Inhibitor2.478271.919785Complete curve; high efficacy-5.60591.210.9515-90.347-18.4273-1.10 0 0 0 0 0 0 0 0 0 0-92.3794-29.4176-25.4576-10.6267-18.3361-13.1226-18.0422-51.5862-63.4387-81.7748-84.6589-92.3794QC'd by Microsource
Inhibitor2.685576.254185Complete curve; high efficacy-5.5711.50950.9645-93.4891-17.235-1.10 0 0 0 0 0 0 0-83.3595-19.1979-15.5958-20.1946-17.5552-53.8059-81.8551-105.9967-83.3595QC'd by Specs
Inhibitor3.013193.599885Complete curve; high efficacy-5.5214.0950.9841-106.6274-13.0276-1.10 0 0 0 0 0 0 0-100.9847-15.8586-12.6799-7.6231-13.2588-38.4269-100.335-118.4749-100.9847QC'd by Chem Div
Inhibitor2.208770.786885Complete curve; high efficacy-5.65591.46410.9882-83.9058-13.119-1.10 0 0 0 0 0 0 0 0 0 0-80.3383-14.6034-13.7105-8.1697-17.0327-13.9823-20.0222-32.5347-69.34-76.772-86.3228-80.3383QC'd by Prestwick Chemical; Inc.
Inhibitor16.9441355.352885Complete curve; high efficacy-4.7711.10.9993-356.9435-1.5907-1.10 0 0 0 0 0 0 0-318.1315-3.9948-2.9251-4.53120-40.0216-141.0144-284.0357-318.1315QC'd by Enamine
Inhibitor5.358275.688784Complete curve; high efficacy-5.2711.10.986-94.241-18.5523-1.10 0 0 0 0 0 0 0-92.9398-25.1237-17.5814-17.053-18.0751-44.0369-68.5795-88.598-92.9398QC'd by Jeff Aube - Univ. of Kansas - MLI CMLD
Inhibitor0.7569135.583784Complete curve; high efficacy-6.1211.34370.7835-54.498981.0848-1.11 0 0 0 1 0 0 00114.033182.571172.543333.2174-170.3018-49.8526-108.21670QC'd by Sergey Kozmin - Univ. of Chicago - MLI CMLD
Inhibitor4.775597.071984Complete curve; high efficacy-5.3210.80.9918-103.7002-6.6283-1.10 0 0 0 0 0 0 0-94.1135-1.4836-13.9984-10.0011-18.7058-41.6061-71.5982-94.9636-94.1135QC'd by Key Organics Ltd.
Inhibitor3.793376.191984Complete curve; high efficacy-5.4211.10.9724-84.3357-8.1438-1.10 0 0 0 0 0 0 0-80.18290.3249-17.896-10.6249-19.5352-32.7938-69.8932-81.1131-80.1829QC'd by ChemBridge
Inhibitor3.013169.492584Complete curve; high efficacy-5.5211.55790.9812-74.2039-4.7114-1.10 0 0 0 0 0 0 0-65.987-5.0213-5.2016-3.1865-8.3924-32.9126-65.2042-82.0627-65.987QC'd by Asinex Ltd.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-activator-f1f2f3f4
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0008905393 uMActivity at 0.00133 uMActivity at 0.00260 uMActivity at 0.00423 uMActivity at 0.00779 uMActivity at 0.011 uMActivity at 0.023 uMActivity at 0.033 uMActivity at 0.070 uMActivity at 0.092 uMActivity at 0.148 uMActivity at 0.213 uMActivity at 0.447 uMActivity at 0.637 uMActivity at 1.271 uMActivity at 1.910 uMActivity at 3.487 uMActivity at 5.719 uMActivity at 10.47 uMActivity at 17.11 uMActivity at 29.50 uMActivity at 51.33 uMActivity at 83.79 uMActivity at 153.7 uMActivity at 271.3 uMActivity at 313.8 uMCompound QC
Activator112.20187915.679100Partial curve; partial efficacy-3.954.95490.9747782.4016-133.27742.20 0 0 0 0 0 0 06550.84315.03831.4327-1.8529-0.749-1.2828-0.8048-0.22086550.8431QC'd by Asinex Ltd.
Activator112.201819185.7415100Partial curve; partial efficacy-3.954.95490.974118856.4676-329.27382.20 0 0 0 0 0 0 015872.4475-8.7565-6.44080.7001-5.8905-4.8567-9.6925-5.186515872.4475QC'd by UrkORgSynthesis Ltd
Activator112.20182376.3081100Partial curve; partial efficacy-3.954.50450.96332450.525774.21752.20 0 0 0 0 0 0 01992.2973-3.5317-4.719354.518428.631718.0366392.2696419.74541992.2973QC'd by ChemBridge
Activator1005725.9134100Partial curve; partial efficacy-44.0450.99545798.94273.02862.20 0 0 0 0 0 0 04931.07310.88030.5649-0.79113.818542.4751348.67511565.75484931.0731QC'd by NCI Chemotherapeutic Agents Repository
Activator15.8489881.223293Complete curve; high efficacy-4.82.25260.9634878.8998-2.32341.10 0 0 0 0 0 0 0728.8831-4.2226-4.7068-6.1137-1.092920.5614426.6125996.485728.8831QC'd by Asinex Ltd.
Activator1001997.138290Partial curve; high efficacy-44.0450.99832014.320917.18262.10 0 0 0 0 0 0 01721.64183.45253.3783.98239.347632.206571.663507.92931721.6418QC'd by Asinex Ltd.
Activator7.9433108.365383Complete curve; high efficacy-5.11.210.9975113.12734.7621.10 0 0 0 0 0 0 0108.98595.39883.16413.682813.914628.618979.4348108.9185108.9859QC'd by Sigma Chemical Company
Activator25.118997.527781Complete curve; high efficacy-4.61.96730.9962100.57073.0431.10 0 0 0 0 0 0 095.23746.18913.79460.66732.34614.271527.873494.956595.2374QC'd by InterBioScreen
Activator25.063866.323780Complete curve; high efficacy-4.6011.96730.971468.90312.57941.10 0 0 0 0 0 0 0 0 0 062.28613.0694-0.84460.65480.83983.1961.3298.84319.809419.514263.225762.2861QC'd by Labotest
Activator31.6228320.503480Complete curve; high efficacy-4.53.19250.9981307.6914-12.8121.10 0 0 0 0 0 0 0307.0772-15.3847-10.2656-16.2349-18.82421.575514.2479288.2493307.0772QC'd by Asinex Ltd.
Activator1001250.315172Partial curve; high efficacy-43.29750.98911276.083525.76852.10 0 0 0 0 0 0 01037.46636.76246.94936.72769.584724.545121.6531390.61691037.4663QC'd by Enamine
Activator112.20181092.625571Partial curve; high efficacy-3.954.95490.99661125.057332.43182.10 0 0 0 0 0 0 0942.259160.508746.391241.266336.193223.219115.6355148.326942.2591QC'd by Chem Div
Activator112.20181105.299770Partial curve; high efficacy-3.954.50450.99981105.0358-0.26392.10 0 0 0 0 0 0 0894.04191.4284-3.389-3.9616-0.18640.77246.7469165.5024894.0419QC'd by Chem Div
Activator1001065.59368Partial curve; high efficacy-42.95230.95151111.000645.40762.10 0 0 0 0 0 0 0881.7465-2.6974-2.14370.95036.938571.8385203.0705370.0237881.7465QC'd by ChemBridge
Activator100908.159763Partial curve; high efficacy-42.30310.984930.232822.07312.10 0 0 0 0 0 0 0707.9397-2.3217-0.4363-1.2562.350233.6888101.7463350.2479707.9397QC'd by InterBioScreen
Activator112.2018806.059962Partial curve; high efficacy-3.954.95490.9966816.201610.14172.10 0 0 0 0 0 0 0676.7841.27153.39650.67385.39157.092142.5928122.1389676.784QC'd by NCI Chemotherapeutic Agents Repository
Activator112.2018783.792462Partial curve; high efficacy-3.954.95490.9997789.93116.13872.10 0 0 0 0 0 0 0655.00097.20577.65892.2588-0.34564.789911.3778112.2218655.0009QC'd by Maybridge
Activator100816.162161Partial curve; high efficacy-43.24750.987832.455416.29332.10 0 0 0 0 0 0 0673.5076-6.24851.84670.25863.852314.682781.096254.4096673.5076QC'd by TimTec
Activator100704.591758Partial curve; high efficacy-43.24750.9989709.34234.75062.10 0 0 0 0 0 0 0571.12910.7768-0.8073-0.51952.84717.869421.5244216.3485571.1291QC'd by Chem Div
Activator100588.690455Partial curve; high efficacy-44.95490.9978589.48410.79372.10 0 0 0 0 0 0 0528.2116-8.0271-8.2801-5.8459-1.28170.261218.8362129.6249528.2116QC'd by Specs
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-activator-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent activators are ranked higher than compounds that showed apparent inhibition.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = 1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == 1.2 || ratio.curve_class == 2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds also have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00123 uMActivity at 0.00246 uMActivity at 0.00610 uMActivity at 0.00630 uMActivity at 0.011 uMActivity at 0.025 uMActivity at 0.045 uMActivity at 0.067 uMActivity at 0.120 uMActivity at 0.202 uMActivity at 0.314 uMActivity at 0.611 uMActivity at 1.089 uMActivity at 1.568 uMActivity at 3.058 uMActivity at 5.503 uMActivity at 7.834 uMActivity at 15.29 uMActivity at 27.41 uMActivity at 39.61 uMActivity at 75.76 uMActivity at 149.6 uMActivity at 201.4 uMActivity at 319.7 uMActivity at 605.8 uMActivity at 817.0 uMCompound QC
Inactive04.95490.8563-9.9979-3.18240 0 0 0 0 0-8.823-2.9167-5.5515-1.8183-11.2482-10.2408-8.823QC'd by Microsource
Inactive01.53860.5644-4.854640 0 0 0 0 1-7.5471-0.6835-9.0455-3.7039-1.19033.153-7.5471QC'd by Microsource
Inactive04.95490.431-21.09492.199340 0 0 0 0 0-29.6624-1.0839-27.7771-29.2982-9.5254-9.846-29.6624QC'd by Microsource
Inactive04.95490.3341-1.3603-6.912440 0 0 0 0 1-15.5699-9.927-2.5767-5.8552-8.5221-2.3836-15.5699QC'd by Microsource
Inhibitor0.891314.13510Complete curve; partial efficacy; poor fit-6.052.12110.6534-22.6728-8.5377-1.40 0 0 0 0 0-21.1521-8.7814-12.9514-21.2535-30.9774-17.0722-21.1521QC'd by Microsource
Inactive03.1320.47250.5-4.228440 0 0 0 0 0-0.2612-1.9763-2.0592-8.107-2.12880.8201-0.2612QC'd by Microsource
Inactive04.95490.4917-10.967-2.314940 0 0 0 0 0-10.1405-1.5124-2.5506-5.4129-17.8892-4.0897-10.1405QC'd by Microsource
Inactive03.990.5924-19.9348040 0 0 0 0 0-28.6957-6.23025.7918-15.0449-23.6413-7.309-28.6957QC'd by Microsource
Inactive04.95490.4102-6.1308540 0 0 0 0 0-4.3550.82898.6021-2.8349-16.3592.161-4.355QC'd by Microsource
Inactive04.95490.369-1.5-14.336940 0 0 0 0 1-9.3021-12.78082.0015-0.2528-12.58754.4401-9.3021QC'd by Microsource
Inhibitor0.707923.62210Complete curve; partial efficacy; poor fit-6.153.06540.6513-24.5288-0.9067-1.40 0 0 0 0 1-13.9864-1.5889-9.6741-27.4469-33.3677-12.1786-13.9864QC'd by Microsource
Inactive04-22.4775-11.6889-11.6628-13.5576-20.9035-8.6191-22.4775QC'd by Microsource
Inactive00.80.7088-25.4933-11.691840 0 0 0 0 0-24.5778-16.5266-8.0765-17.2318-20.0221-22.1348-24.5778QC'd by Microsource
Inhibitor0.177819.99850Complete curve; partial efficacy; poor fit-6.754.95490.6578-21.9347-1.9361-1.40 0 0 0 0 0-23.6561-4.5301-30.7789-20.7284-19.2667-15.4849-23.6561QC'd by Microsource
Inactive010.9184-24.9585-2.733140 0 0 0 0 1-15.8401-9.7776-20.4013-20.4952-26.2154-25.1202-15.8401QC'd by Microsource
Inactive04-16.8662-15.0798-16.9114-17.163-13.1564-16.5558-16.8662QC'd by Microsource
Inactive047.75753.31266.13836.2047-2.02096.22127.7575QC'd by Microsource
Inactive043.75979.79097.02243.0975-6.896512.31463.7597QC'd by Microsource
Inactive04.95490.6335-4.9129640 0 0 0 0 0-8.84676.11915.34965.0731-9.09412.984-8.8467QC'd by Microsource
Inactive04.95490.7097-7.2734040 0 0 0 0 0-5.9151.1538-1.05870.2688-11.4778-4.1213-5.915QC'd by Microsource
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:
External ID: epac2-inhibitor-v2
Protocol: Briefly, three uL of reagents (100 nM EPAC2, 250 nM RAP1B-BODIPY-GDP, 50 uM GDP) were dispensed into a 1536-well Greiner black solid-bottom medium binding assay plate. Controls and test compounds (23 nL) were transferred to the plate via a Kalypsys pin tool equipped with a 1536-pin array. The plates were centrifuged at 1,000 rpm for 15 seconds followed by 5 minute incubation at room temperature. The assay plates were read at 5 minute intervals for 30 minutes in the ViewLux plate reader using 480nm excitation and 540nm emission filters. The results were normalized to the agonist positive control of 6.5 mM cAMP.
Comment: Disclaimer:
Although all reasonable efforts have been made to ensure the accuracy and reliability of the data, caution should be exercised when interpreting the results as artifacts are possible from nonspecific effects such as assay signal interference. The curve fitting and activity calls presented here are based on the NCATS analysis methods.

Compound Ranking:
1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, with a ratio activity curve class of 4, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. For a ratio activity curve class = -1.1, score = 80+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 && abs(ratio.max_response) > 6*10, score = 60+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -2.1 || ( ratio.curve_class==-2.2 && abs(ratio.max_response) > 6*10), score = 40+abs((log_ac50+4.5)*inf_activity/20). For ratio.curve_class == -1.2 || ratio.curve_class == -2.2, score = 20+abs((log_ac50+4.5)*inf_activity/20). Inconclusive compounds, with a donor curve class other than 4, have PUBCHEM_ACTIVITY_SCORE of 10. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0009200000 uMActivity at 0.00184 uMActivity at 0.00456 uMActivity at 0.00471 uMActivity at 0.00850 uMActivity at 0.018 uMActivity at 0.034 uMActivity at 0.050 uMActivity at 0.090 uMActivity at 0.151 uMActivity at 0.235 uMActivity at 0.457 uMActivity at 0.814 uMActivity at 1.171 uMActivity at 2.284 uMActivity at 4.113 uMActivity at 5.853 uMActivity at 11.42 uMActivity at 20.49 uMActivity at 29.59 uMActivity at 56.64 uMActivity at 111.7 uMActivity at 150.6 uMActivity at 238.8 uMActivity at 452.6 uMActivity at 611.0 uMCompound QC
Inactive03.62720.8626-16.9749340 0 0 0 0 0-11.35224.4122-0.18693.8551-9.0486-22.4791-11.3522QC'd by SigmaAldrich
Inactive01.210.9115126.540 0 0 0 0 03.087922.522231.966122.849617.27176.55893.0879QC'd by NCI
Inactive00.30.7243-12.89953840 0 0 0 0 0-10.749628.516821.95465.20966.073811.3009-10.7496QC'd by Prestwick Chemical; Inc.
Inactive04.95490.8029-15.6993-1.540 0 0 0 0 0-11.416-1.5504-1.249-4.6581-0.42660.4639-11.416QC'd by BIOMOL
Inactive04.95490.6678-24.46023.435940 0 0 0 0 1-5.46512.8722.434-38.4104-25.2406-9.2436-5.4651QC'd by BIOMOL
Inactive02.40640.421511740 0 0 0 0 05.872919.320214.88288.633224.90711.29795.8729QC'd by BIOMOL
Inactive00.60.7078-8.313814.540 0 0 0 0 0-10.777711.81871.99321.9062-11.5115-0.0866-10.7777QC'd by BIOMOL
Inactive03.990.91612.52940 0 0 0 0 011.321625.351110.278212.692812.042515.059611.3216QC'd by BIOMOL
Inactive04.95490.7598-8.0307240 0 0 0 0 0-6.9632-1.91335.8317-9.609-8.7246-6.018-6.9632QC'd by SigmaAldrich
Inactive00.70.6402-18.8089-2.373540 0 0 0 0 0-14.8407-3.9662-6.7181-0.3112-9.968-9.2615-14.8407QC'd by Microsource
Inactive04.95490.9739-11.7501240 0 0 0 0 0-11.69293.0780.24372.2683-12.7084-10.568-11.6929QC'd by Microsource
Inactive00.50.7605-11.0605640 0 0 0 0 0-14.63373.6876-3.5123-6.8473-7.5675-5.2666-14.6337QC'd by BIOMOL
Inactive04-7.534.7778-6.7829-15.1322-23.6499.0847-7.53QC'd by Prestwick Chemical; Inc.
Inactive04.95490.6409-3.29491440 0 0 0 0 112.981817.6514.10220.62192.497-3.579112.9818QC'd by BIOMOL
Inactive01.82650.7407-32.7287-10.937340 0 0 0 0 0-28.3802-13.7631-19.1044-5.7811-12.8137-32.2739-28.3802QC'd by Tocris
Activator39.810746.5380Single point of activity-4.44.44950.745456.645810.107830 0 0 0 0 117.141513.503225.583214.4646.953849.110217.1415QC'd by SigmaAldrich
Inactive04.95490.5359-17.72063.540 0 0 0 0 0-16.8505-6.86613.1002-5.400912.3928-11.0619-16.8505QC'd by SigmaAldrich
Inactive04.95490.6571.108210.540 0 0 0 0 110.717211.35185.125315.2488-0.32652.247610.7172QC'd by Prestwick Chemical; Inc.
Inactive00.70.842-14.440710.540 0 0 0 0 0-8.700613.02386.27927.28923.56910.9878-8.7006QC'd by BIOMOL
Inactive01.010.87182.4065-26.947540 0 0 0 0 1-20.1909-25.9748-30.373-20.9376-21.2882-7.9946-20.1909QC'd by Prestwick Chemical; Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4513082
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=0.24%
Inhibition=4.58%
Inhibition=-0.3%
Inhibition=-0.3%
Inhibition=-0.04%
Inhibition=-0.04%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=0.03%
Inhibition=0%
Inhibition=0.03%
Inhibition=0%
Inhibition=-0.27%
Inhibition=-0.27%
Inhibition=-0.08%
Inhibition=-0.08%
Inhibition=14.41%
Inhibition=0.39%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:23209 靶标:N/A
External ID: UIHTS20180925
Protocol: Assay overview:
The purpose of this assay is to identify test compounds that differentially kill either epithelial cells or mesenchymal cells, critical components of EMT. The PC-3E+ and TEM4-18 cell lines, characterized as epithelial cells and mesenchymal cells respectively, were established in Henry Lab (Ref 1). For potential discriminative modulators of EMT, the two cells lines were labeled with GFP and mCherry respectively, and co-cultured together to eliminate those hits that non-discriminatingly kill both epithelial cells and mesenchymal cells by cytotoxicity irrelevant to the EMT properties.
Protocol for the EMT project:
The primary screening data were generated as described in HTS assay protocol table (Ref 2).

Table 1: HTS assay protocol table
Step Parameter Value Description
1. Plate cells 200 uL By MultiFlo. PC3E GFP 2,000 cells/ well and TEM418 mCherry 2,000 cells/well (1:1). Overnight incubation
2. Remove media Flip the plate
3. Add fresh media 150 uL By MultiFlo
4. Controls 200 uL C01-H01, C12 -H12, Hygromycin dose response from H to C were positive control. Wells A01, B01, A12 and B12 were negative control
5. Library 50 uL MSSP library 1 uM final from middle plate in full media
6. Incubation 72 hrs 37 C and 5% CO2
7. Assay readout GFP and mCherry channel imaging Perkin Elmer Operetta high content imaging system, with Harmony image analysis software.
8. Image analysis Green cells and Read cells counting Normalized to the average cell number of well B1 and B12 (no inhibition of cell viability) controls on each plate to get relative cell viability for each well.
9. Hit selection 11 hits The hit criteria for preferential cell killing are compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal
0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing OR Greencells_Normalized is
lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent
by itself for Green cell killing.

The primary screening data (imaging data) were translated into Green or Red cell numbers in each well in the data file.
Comment: Preferential killing compounds are considered as active hits (score of 100) when meeting one of two groups of criteria:

1. Compounds that Redcells_Normalized is lower or equal 0.41, GreenCells_Normalized is higher or equal 0.55, RedCells/GreenCells_Normalized ratio is lower or equal 0.65, and Non-fluorescent by itself for Red cell killing.

OR

2. Greencells_Normalized is lower or equal 0.41, RedCells_Normalized is higher or equal 0.46, RedCells/GreenCells_Normalized ratio is higher or equal 1.8 and Non-fluorescent by itself for Green cell killing.
No. of GreenCellsNo. of RedCellsGreenCells_NormalizedRedCells_NormalizedRedCells/GreenCells_Normalized
178911800.881.081.22
196110810.970.991.02
187612910.931.181.27
224410941.1110.9
227512101.121.110.98
199513980.981.281.3
212312931.051.181.13
228112271.131.121
196410900.9711.03
211012951.041.181.14
234213611.161.241.08
201413160.991.21.21
2021127011.161.16
216012871.071.181.1
2022119711.091.1
179810820.890.991.11
193811991.081.060.98
200012601.121.110.99
197112011.11.060.96
210011301.1710.85
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:DNA polymerase kappa [Homo sapiens]
External ID: PolK100
Protocol: Three microliters of reagents (buffer in column 3 and 4 as negative control and 10 nM Pol kappa in columns 1, 2, and 5-48) were dispensed into a 1536-well black solid-bottom plate. Compounds (23 nL) were transferred via Kalypsys pin tool equipped with 1536-pin array. The plates were then incubated for 15 min at room temperature, and 1 uL substrate (50 nM final concentration) were then added to start the reaction and kinetically read twice at 0 min and 10 min on the Viewlux reader
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.0003270000 uMActivity at 0.0007732774 uMActivity at 0.00163 uMActivity at 0.00369 uMActivity at 0.00818 uMActivity at 0.020 uMActivity at 0.030 uMActivity at 0.047 uMActivity at 0.101 uMActivity at 0.151 uMActivity at 0.243 uMActivity at 0.477 uMActivity at 0.759 uMActivity at 1.287 uMActivity at 2.393 uMActivity at 3.818 uMActivity at 6.336 uMActivity at 11.99 uMActivity at 19.37 uMActivity at 31.37 uMActivity at 60.11 uMActivity at 107.2 uMActivity at 158.4 uMActivity at 229.0 uMCompound QC
Inactive40 0 0 0 01.4694-3.5669-6.2352.85861.80421.4694QC'd by "Chem Div"
Inactive40 0 0 0 0-4.26318.22188.081110.2927-3.9947-4.2631QC'd by "Chem Div"
Inactive40 0 0 0 06.03690.3398-2.1048-8.1695-3.68226.0369QC'd by "Chem Div"
Inactive4-2.05651.7294-3.5894-1.2575-0.5402-2.0565QC'd by "Chem Div"
Inactive40 0 0 0 12.31491.00484.6369-1.9963-3.35432.3149QC'd by "Chem Div"
Inactive47.27487.15156.13721.51975.23327.2748QC'd by "Chem Div"
Inactive40 0 0 0 01.006-3.3873-7.786-9.3037-9.17611.006QC'd by "Chem Div"
Inactive40 0 0 0 0-0.0368-9.4458-10.5155-9.0065-12.9141-0.0368QC'd by "Chem Div"
Inactive40 0 0 0 02.6-7.8084-12.3007-2.0954-6.68872.6QC'd by "Chem Div"
Inactive40 0 0 0 0-11.4867-18.9051-17.4955-19.0735-9.6682-11.4867QC'd by "Chem Div"
Inactive40 0 0 0 0-7.5605-17.2173-11.0038-16.5656-22.4025-7.5605QC'd by "Chem Div"
Inactive4-7.5451-1.1939-1.3084-5.8268-5.3206-7.5451QC'd by "Chem Div"
Inactive40 0 0 0 1-5.5852-4.3753-1.0046-3.1641-10.1524-5.5852QC'd by "Chem Div"
Inactive40 0 0 0 01.1172-6.03917.01189.04461.65331.1172QC'd by "Chem Div"
Inactive42.33591.25181.6626-0.9325-0.91942.3359QC'd by "Chem Div"
Inactive40 0 0 0-19.53540.3984-4.11472.1883-19.5354QC'd by "Chem Div"
Inactive4-5.6552-4.6769-1.9378-0.5867-3.224-5.6552QC'd by "Chem Div"
Inactive4-11.3738-10.4148-13.8912-10.4252-7.8961-11.3738QC'd by "Chem Div"
Inactive4-6.1571-8.7102-2.9113-5.2229-3.4369-6.1571QC'd by "Chem Div"
Inactive40 0 0 0 1-7.3803-8.8177-11.1654-6.5301-15.9483-7.3803QC'd by "Chem Div"
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Severe acute respiratory syndrome coronavirus 2
External ID: CHEMBL4303805
Protocol: N/A
Comment: Target ChEMBL ID: CHEMBL4303835
ChEMBL Target Name: SARS-CoV-2
ChEMBL Target Type: ORGANISM - Target is a complete organism
Relationship Type: N - Non-molecular target assigned
Confidence: Target assigned is non-molecular

Data Source: SARS-CoV-2 Screening Data
Standard TypeStandard RelationStandard ValueStandard UnitsData Validity Comment
Inhibition=-11.52%Outside typical range
Inhibition=5.09%
Inhibition=-1.71%
Inhibition=3.69%
Inhibition=22.47%
Inhibition=8.51%
Inhibition=-6.86%
Inhibition=-6.18%
Inhibition=-2.07%
Inhibition=3.91%
Inhibition=-5.9%
Inhibition=-2.45%
Inhibition=-5.55%
Inhibition=6.31%
Inhibition=-1.08%
Inhibition=12.7%
Inhibition=0.37%
Inhibition=8.88%
Inhibition=11.63%
Inhibition=-1.96%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Cellular tumor antigen p53
External ID: HMS1485
Protocol: Prior to screening, HeLa cells were transduced with a lentivirus carrying the vector PHAGE-N CMVt N-RIG3 p53(R273C) encoding constitutively expressed SGFP2 fused to histone 2B and mRuby-p53(R273C). Following transduction, the cells were selected using neomycin and fluorescent activated cell sorting. The day before the compound treatment, cells were plated (750 cells/well) in a final volume of 30 L/well of Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% (v/v) fetal bovine serum using a Thermo Combi. Plates were spun for 45 s at 500 rpm and incubated overnight (~24 h) at 37 degrees C, 5% CO2.

On the day of the screening, 33 nL of each compound was transferred to assay wells via a custom pin-transfer workstation. Additionally, 33 nL of positive (Velcade 300 M) and negative (DMSO 100%) controls were transferred to each plate into the corresponding columns that did not contain experimental compounds. For every compound library plate, there were two daughter plates (A and B). Plates were stacked 5 high, covered with lids, and incubated at 37 degrees C for 24h and 48h.

Assay plates were read using an Acumen Laser Scanning Cytometer 24h and 48h after compound treatment, using the following settings: For SGFP2 (channel 2), the 488 nm laser was used, with 6 mW output, 600 voltage gain and sensitivity threshold at 1; and for mRuby (channel 3), the 561 nm laser was used, with 8 mW output, 600 voltage gain and sensitivity threshold at 1.
Comment: Total nuclei and %p53 positive was calculated for all wells at 24 and 48h using the Cellista software. Percentage of p53 positive cells values were normalized to the positive and negative controls to determine a normalized percent of p53 activation. This was done on a per plate basis. The proteasome inhibitor Velcade (Adipogen, AG-CR1-3602-M005) at 330 nM was used as positive control while only the vehicle (DMSO, Sigma, D8418, 0.1% final concentration) was used as negative control. From these values the following normalized values were calculated (for both 24h and 48h): Normalized total nuclei = (total nuclei in experimental well / plate average negative control total nuclei) * 100. Normalized %p53 positive = (%p53 positive in experimental well - plate average negative control %p53 positive cells) / (plate average positive control %p53 positive cells - plate average negative control %p53 positive cells) * 100.

Based on the normalized percent p53 positive values, a compound was considered active when replicate average normalized % p53 positive cells > 50% for either or both time points. Activity scores were based on the replicate average normalized %p53 positive cells at 24hr. Values less than 0 were set to 0, and values > 100 were set to 100 (100% activity). Compounds with an activity score > 50 were considered active; some compounds were scored active despite having an activity score < 50 since % p53 positive cells was > 50% only at 48hr.

The average normalized total nuclei values were categorized as:
Very Low: x < 25%
Low: 25% < X > 50%
Medium: 50% < X > 75%
High: x < 75%

The average normalized % of p53 positive cells values were categorized as:
Low: x < 25%
Medium: 25% < X > 50%
Strong: 50% < X > 75%
Very Strong: x < 75%

Compounds that scored as strong or very strong in this classification (at either time point) were selected for follow up.
TotalNuclei_24h_A%Pos_24h_ATotalNuclei_24h_B%Pos_24h_BTotalNuclei_48h_A%Pos_48h_ATotalNuclei_48h_B%Pos_48h_BTotalNuclei_Norm_A_24h%Pos_Norm_A_24hTotalNuclei_Norm_B_24h%Pos_Norm_B_24hTotalNuclei_Norm_A_48h%Pos_Norm_A_48hTotalNuclei_Norm_B_48h%Pos_Norm_B_48hAvg_TotalNuclei_Norm_24hAvg_%Pos_Norm_24hAvg_TotalNuclei_Norm_48hAvg_%Pos_Norm_48hViability 24hViability 48hHit 24hHit 48hMolar Concentration
12080.16612330.32415340.065215670.128107.52413010.014207932114.25262060.301056209111.5408212-0.200936304115.8595194-0.078440722110.88837530.15763207113.7001703-0.139688513HighHighLowLow123 uM
12780.078211730.34116440.30415250.262113.754833-0.105094533108.69288240.324276435119.53918520.073652809112.7541590.076453966111.22385770.109590951116.14667210.075053388HighHighLowLow41 uM
11910.33612510.2414840.13515530.258106.01095940.245203592115.92054210.186320973107.9052012-0.120675332114.82439930.071830244110.96575070.215762282111.3648002-0.024422544HighHighLowLow13.7 uM
12350.0811129015390.06514630.273109.9274012-0.101289898104.615741-0.141493985111.9043832-0.201166278108.17005550.089169202107.2715711-0.121391942110.0372193-0.055998538HighHighLowLow4.6 uM
12740.078511270.17716430.36514100.213113.3987928-0.104686893104.43041640.100269547119.46647280.143794919104.25138630.019813371108.9146046-0.002208673111.85892950.081804145HighHighLowLow1.5 uM
12120118401575013830.0723107.8801702-0.211352536109.7121677-0.141493985114.5220296-0.27590787102.2550832-0.142826051108.796169-0.176423261108.3885564-0.209366961HighHighLowLow500 nM
123201268013610.073514110.142109.6603711-0.211352536117.4958012-0.14149398598.96157604-0.191392377104.3253235-0.062257695113.5780861-0.176423261101.6434498-0.126825036HighHighLowLow10 mM
11450.087311640.25814730.067914790.203101.9164975-0.092729471107.85892160.210907095107.1053648-0.197831653109.35304990.008254066104.88770950.059088812108.2292074-0.094788793HighHighLowLow3.333 mM
13740.29111470.087216030.37414470.0691122.29979690.184057682106.2836625-0.022387884116.55797680.154143755106.987061-0.146525029114.29172970.080834899111.77251890.003809363HighHighLowLow1.111 mM
12080.1661215014450.13815520.0644107.52413010.014207932112.5846991-0.141493985105.0694176-0.11722572114.7504621-0.151957902110.0544146-0.063643027109.9099399-0.134591811HighHighLowLow370 uM
11270.17712080.24814480.20713550.221100.31431670.02915471111.9360630.197248139105.2875548-0.037884645100.18484290.029060815106.12518990.113201424102.7361989-0.004411915HighHighLowLow123 uM
12640.079111330.088314210.49313650.147112.5086924-0.103871615104.9863902-0.020885398103.324320.290978363100.9242144-0.056478042108.7475413-0.062378506102.12426720.11725016HighHighLowLow41 uM
13160.0761210015700.31814720.204117.1372145-0.108083888112.1213876-0.141493985114.15846760.089750998108.83548980.009409997114.6293011-0.124788937111.49697870.049580497HighHighLowLow13.7 uM
13470.14812700.078715580.25715460.259119.8965258-0.010250432117.6811258-0.033997997113.28591880.019608888114.30683920.072986175118.7888258-0.022124215113.7963790.046297531HighHighLowLow4.6 uM
12110.16511810.33914800.2714510.276107.79116020.012849134109.43418080.321544644107.61435160.034557207107.28280960.092636994108.61267050.167196889107.44858060.0635971HighHighLowLow1.5 uM
11920.083912690.078814800.2715360.13106.0999694-0.097349384117.5884635-0.033861407107.61435160.034557207113.5674677-0.076128861111.8442165-0.065605396110.5909096-0.020785827HighHighLowLow500 nM
1241011680.17114890.26914690.136110.4614614-0.211352536108.22957090.092074173108.26876320.033407336108.6136784-0.069193278109.3455161-0.059639182108.4412208-0.017892971HighHighLowLow10 mM
11390.08781049013460.29713270.226101.3824372-0.09205007297.2027567-0.14149398597.870890050.06560371498.114602590.03484046899.29259695-0.11677202997.992746320.050222091HighHighLowLow3.333 mM
11890.084111490.08714700.3414030.214105.8329393-0.097077625106.4689871-0.022661063106.88722760.115048152103.73382620.020969302106.1509632-0.059869344105.31052690.068008727HighHighLowLow1.111 mM
1239011330.26514760.20313910.431110.2834414-0.211352536104.98639020.220468365107.323502-0.042484127102.84658040.271806223107.63491580.004557914105.08504120.114661048HighHighLowLow370 uM
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ICCB-Longwood/NSRB Screening Facility, Harvard Medical School 靶标:Chain A, Poliovirus Polymerase With Gtp
External ID: HMS750
Protocol: The stalled elongation complex used as a substrate in the screening assay was generated by pre-incubating 600 nM 3Dpol with 12 nM 5' fluorescein labeled 8-6 PETE RNA and 240 nM ATP for 30 minutes at room temperature in 50 mM HEPES, pH 7.0, 40 mM NaCl, 1.5 mM magnesium acetate, 60 microM ZnCl2, 4 mM DTT, and 0.1% Igepal detergent. This solution was dispensed into 384-well microplates (Corning 3710) at a volume of 25 microL/well. Experimental compounds were added by robotic pin transfer at 100 nL/well.

After an incubation time of ~60 min, the total fluorescence and fluorescence polarization signals from the labeled RNA were measured with Perkin Elmer EnVision microplate readers. This first reading provided data indicating whether compounds interfered with RNA binding to the stalled elongation complex. Polymerase elongation activity was then tested by adding 5 microL of a solution containing GTP, CTP, and UTP at 1.2 microM each, resulting in a final concentration of 200 nM for each of the four NTPs and 16.7 microg/ml for the compounds. This allowed for elongation to the end of the RNA template, and assay data were obtained with a second reading done after an incubation period of ~60 min, which is four times longer than the ~15 min needed for elongation under non-inhibited conditions.
Comment: Potential inhibitors were identified using a correlation plot combining standard Z-scores with an elongation efficiency measurement. A Z-score for each compound was calculated by the normal method of Z=(FPcompound-FPplate_mean)/StdDevplate_mean. An elongation efficiency value (FP %Elongation) was then calculated as E=(FPcompound-FPpositive)/(FPnegative-FPpositive), which reflects how the FP signal obtained in the presence of a compound compared to those of the unelongated positive controls (FPpositive) and fully elongated negative controls (FPnegative). Compounds that gave a FP signal greater than the starting material but less than the fully elongated controls thus had E values between 0% and 100%, while compounds that caused the RNA to dissociate from 3Dpol had negative E values due to the FP value associated with free RNA being lower than the unelongated FPpositive value. Finally, the elongation reaction also results in an increase in the total fluorescence intensity due to deprotonation of the fluorescein as it approaches the positively charged polymerase surface, providing an additional assessment of elongation. Compounds that resulted in total fluorescence %Elongation higher than that of the fully elongated control samples were rejected from the analysis. Positives were defined as having experimental FP Z-scores < -0.5 and FP %Elongation < 90%. Activity scores were calculated based on FP %Elongation. FP %Elongation <= 0 was scored as 100 for activity; FP %Elongation >= 100 was scored as 0 for activity. FP %Elongation values between 0 and 100 were subtracted from 100 to generate activity scores.
Fluorescence PolarizationTotal IntensityZ-score_FPZ-score_Total Intensity% Elongation_FP% Elongation_Total IntensityFluorogenic
256.736080052-0.10.3102113
255.736170657-0.30.3101113
256.935420114-0.1-0.3102107
255.235741699-0.40100110
257.5352271250-0.5103105
256.635252352-0.2-0.5102105
259358490650.30.1105111
261359033110.70.1107111
259.7359711690.50.2106112
260.5362367040.60.4107114
257.43614408900.3103113
260.7361582050.60.3107113
260.4362549810.60.4107114
261.8367999010.90.9108119
257.7364981250.10.6103116
255.935232080-0.3-0.5101105
256.835726936-0.10102110
257.9363782270.10.5104115
258.7363095110.30.5105115
256.836098037-0.10.3102113
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:NCGC 靶标:N/A
External ID: StopGo1
Protocol: 3000 Hek-293T-WT cells were plated overnight before adding 23 nL of FireFly inhibitors per well using a pintool workstation (Kalypsys) followed by incubation for 4 hr. Luciferase activity was then measured using Amplite Luciferase Reagent.
Comment: Compound Ranking:

1. Compounds are first classified as having full titration curves, partial modulation, partial curve (weaker actives), single point activity (at highest concentration only), or inactive. See data field "Curve Description". For this assay, apparent inhibitors are ranked higher than compounds that showed apparent activation.
2. For all inactive compounds, PUBCHEM_ACTIVITY_SCORE is 0. For all active compounds, a score range was given for each curve class type given above. Active compounds have PUBCHEM_ACTIVITY_SCORE between 40 and 100. Inconclusive compounds have PUBCHEM_ACTIVITY_SCORE between 1 and 39. Fit_LogAC50 was used for determining relative score and was scaled to each curve class' score range.
PhenotypePotencyEfficacyAnalysis CommentActivity_ScoreCurve_DescriptionFit_LogAC50Fit_HillSlopeFit_R2Fit_InfiniteActivityFit_ZeroActivityFit_CurveClassExcluded_PointsMax_ResponseActivity at 0.00457 uMActivity at 0.023 uMActivity at 0.029 uMActivity at 0.047 uMActivity at 0.084 uMActivity at 0.127 uMActivity at 0.212 uMActivity at 0.303 uMActivity at 0.463 uMActivity at 0.774 uMActivity at 1.183 uMActivity at 2.152 uMActivity at 2.856 uMActivity at 4.631 uMActivity at 6.701 uMActivity at 11.26 uMActivity at 16.91 uMActivity at 27.01 uMActivity at 39.83 uMActivity at 57.93 uMActivity at 97.38 uMActivity at 146.4 uMActivity at 210.0 uMActivity at 304.0 uMCompound QC
Inactive04-6.0625-2.3623-0.2802-5.2775-6.0625QC'd by Evotec (US) Inc.
Inhibitor35.481340.773610Single point of activity-4.452.40640.933-44.7736-4-30 0 0 0-35.05580-9.6533-5.4245-35.0558QC'd by Evotec (US) Inc.
Inactive0-5.853.92950.9968-13.4932340 0 0 0-13.15412.8182-11.1738-14.161-13.1541QC'd by UrkORgSynthesis Ltd
Inactive0-5.14.95490.889213.5-3.562340 0 0 1-8.0174-0.4429-6.301911.0739-8.0174QC'd by Evotec (US) Inc.
Inactive04-15.8272-9.3466-13.7699-18.4456-15.8272QC'd by Evotec (US) Inc.
Inactive0-5.72.40640.8108-13.04340.434140 0 0 0-9.5936-0.0549-7.5602-16.7029-9.5936QC'd by Evotec (US) Inc.
Inactive04-11.635-18.2363-13.8009-16.9167-11.635QC'd by Evotec (US) Inc.
Inactive04-12.2857-9.6332-6.6135-15.2325-12.2857QC'd by Evotec (US) Inc.
Activator14.125448.56740Single point of activity-4.851.22210.997536.9973-11.570130 0 0 030.2349-11.1897-5.77248.651130.2349QC'd by Evotec (US) Inc.
Inactive0-6.24.95490.69662-9.596940 0 0 1-6.1109-7.58075.9101-1.5457-6.1109QC'd by Evotec (US) Inc.
Inactive0-5.853.1320.9409-21.4577.540 0 0 0-17.5516.6865-16.2327-25.7975-17.551QC'd by ChemBridge
Inactive04-8.9062-10.0321-8.4923-13.3892-8.9062QC'd by Enamine
Inactive0-4.44.95490.62637.867851.418340 0 0 013.962331.042659.781363.080913.9623QC'd by Asinex Ltd.
Inhibitor19.952638.612510Single point of activity-4.72.33320.9982-39.7401-1.1275-30 0 0 0-36.5455-1.9894-0.5229-9.5594-36.5455QC'd by Evotec (US) Inc.
Inactive0-6.24.95490.9465-11.49182240 0 0 0-6.912316.7569-14.5765-13.2401-6.9123QC'd by ChemBridge
Inactive04-15.3605-14.6287-17.6489-22.4317-15.3605QC'd by Evotec (US) Inc.
Inactive0-5.54.50450.9992-8.294-20.163740 0 0 1-21.4275-20.1364-17.9575-8.5783-21.4275QC'd by Evotec (US) Inc.
Inactive04-15.0697-19.7843-18.2327-16.8712-15.0697QC'd by Evotec (US) Inc.
Inactive0-5.53.990.9996-14.5384240 0 0 1-1.55331.9923-1.6259-14.1987-1.5533QC'd by Asinex Ltd.
Inactive0-4.853.92950.92562.5-10.304640 0 0 02.6164-8.1304-12.3372-6.37372.6164QC'd by Evotec (US) Inc.
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Co-chaperonin GroES
External ID: CHEMBL4392938
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2019
Volume: 29
Issue: 9
First Page: 1106
Last Page: 1112
DOI: 10.1016/j.bmcl.2019.02.028

Target ChEMBL ID: CHEMBL4106139
ChEMBL Target Name: GroEL/GroES
ChEMBL Target Type: PROTEIN COMPLEX - Target is a defined protein complex, consisting of multiple subunits
Relationship Type: D - Direct protein target assigned
Confidence: Direct protein complex subunits assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=100%
Inhibition=72%
Inhibition=66%
Inhibition=98%
Inhibition=99%
Inhibition=96%
Inhibition=98%
Inhibition=81%
Inhibition=98%
Inhibition=100%
Inhibition=99%
Inhibition=99%
Inhibition=89%
Inhibition=102%
Inhibition=94%
Inhibition=79%
Inhibition=49%
Inhibition=96%
Inhibition=99%
Inhibition=97%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Co-chaperonin GroES
External ID: CHEMBL4392939
Protocol: N/A
Comment: Journal: Bioorg Med Chem Lett
Year: 2019
Volume: 29
Issue: 9
First Page: 1106
Last Page: 1112
DOI: 10.1016/j.bmcl.2019.02.028

Target ChEMBL ID: CHEMBL4106139
ChEMBL Target Name: GroEL/GroES
ChEMBL Target Type: PROTEIN COMPLEX - Target is a defined protein complex, consisting of multiple subunits
Relationship Type: D - Direct protein target assigned
Confidence: Direct protein complex subunits assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=98%
Inhibition=86%
Inhibition=85%
Inhibition=66%
Inhibition=89%
Inhibition=101%
Inhibition=101%
Inhibition=94%
Inhibition=100%
Inhibition=99%
Inhibition=101%
Inhibition=77%
Inhibition=62%
Inhibition=100%
Inhibition=93%
Inhibition=65%
Inhibition=87%
Inhibition=80%
Inhibition=101%
Inhibition=98%
HepG2 Cytotoxicity Assay Measured in Cell-Based System Using Plate Reader - 7071-02_Inhibitor_Dose_DryPowder_Activity_Set16
来源:ChEMBL 靶标:Cocaine esterase
External ID: CHEMBL2341911
Protocol: N/A
Comment: Journal: J. Nat. Prod.
Year: 2013
Volume: 76
Issue: 1
First Page: 36
Last Page: 44
DOI: 10.1021/np300628a

Target ChEMBL ID: CHEMBL3180
ChEMBL Target Name: Carboxylesterase 2
ChEMBL Target Type: SINGLE PROTEIN - Target is a single protein chain
Relationship Type: D - Direct protein target assigned
Confidence: Direct single protein target assigned
Standard TypeStandard RelationStandard ValueStandard Units
Inhibition=83%
Inhibition=81%
Inhibition=80.8%
Inhibition=83.8%
Inhibition=80.8%
Inhibition=14.9%